Biogen Idec, Inc. (BIIB) Tops Q4 EPS by 2c; Guides FY12 EPS Below View
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q4 EPS of $1.51, $0.02 better than the analyst estimate of $1.49. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.29 billion.
Biogen Idec, Inc. sees FY2012 EPS of $6.10-$6.20, versus the consensus of $6.32.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Biogen Idec, Inc. sees FY2012 EPS of $6.10-$6.20, versus the consensus of $6.32.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lamar Advertising (LAMR) Misses Q3 EPS by 6c ; Offers Guidance
- CareCloud, Inc. (CCLD) Reports In-Line Q3 EPS
- Netscout Systems (NTCT) Tops Q2 EPS by 2c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
